These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7792467)

  • 1. [Gastroduodenal ulcer disease: update on pathogenesis].
    Wirth HP
    Praxis (Bern 1994); 1995 May; 84(19):570-80. PubMed ID: 7792467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptic ulcer pathophysiology.
    Mertz HR; Walsh JH
    Med Clin North Am; 1991 Jul; 75(4):799-814. PubMed ID: 2072787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Peptic ulcer: a failure of the defense mechanisms of the gastroduodenal mucosa?].
    Chacín J
    G E N; 1990; 44(2):163-70. PubMed ID: 2152272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neurosis and genetic theory of etiology and pathogenesis of ulcer disease].
    Kolotilova ML; Ivanov LN
    Vestn Ross Akad Med Nauk; 2014; (7-8):10-6. PubMed ID: 25562999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Helicobacter pylori in peptic ulcer disease.
    Partipilo ML; Woster PS
    Pharmacotherapy; 1993; 13(4):330-9. PubMed ID: 8361859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etiopathogenetic principles and peptic ulcer disease classification.
    Tytgat GN
    Dig Dis; 2011; 29(5):454-8. PubMed ID: 22095009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pathophysiology of ulcer disease].
    Beglinger C
    Ther Umsch; 1992 Nov; 49(11):743-8. PubMed ID: 1475770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastric secretion and the pathogenesis of peptic ulcer in the Helicobacter pylori infection.
    Konturek PC; Konturek JW; Konturek SJ
    J Physiol Pharmacol; 1996 Mar; 47(1):5-19. PubMed ID: 8777306
    [No Abstract]   [Full Text] [Related]  

  • 9. [Healing peptic ulcer disease with therapy of Helicobacter pylori infection--an overview].
    Leodolter A; Peitz U; Malfertheiner P
    Wien Med Wochenschr; 2001; 151(13-14):300-8. PubMed ID: 11582994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.
    Ohara T; Morishita T; Suzuki H; Masaoka T; Ishii H
    Hepatogastroenterology; 2004; 51(56):338-42. PubMed ID: 15086153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs.
    Quan C; Talley NJ
    Am J Gastroenterol; 2002 Dec; 97(12):2950-61. PubMed ID: 12492176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Helicobacter pylori. New apsects in the pathogenesis of peptic ulcer disease].
    Wagner S; Meran JG; Manns M
    Wien Med Wochenschr; 1992; 142(8-9):162-6. PubMed ID: 1509766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pathophysiology of peptic ulcer disease.
    Brooks FP
    Dig Dis Sci; 1985 Nov; 30(11 Suppl):15S-29S. PubMed ID: 4053922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Helicobacter pylori-related cytokines influence gastric acid secretion and gastric mucosal inflammation in gastroduodenal ulcers].
    Imatani A; Ohara S; Yonechi M; Ohyauchi M; Shimosegawa T
    Nihon Rinsho; 2004 Mar; 62(3):442-7. PubMed ID: 15038084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals.
    Brzozowski T; Konturek PC; Sliwowski Z; Kwiecień S; Drozdowicz D; Pawlik M; Mach K; Konturek SJ; Pawlik WW
    J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():67-79. PubMed ID: 17033106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptic ulcer--current status.
    Brooks FP
    Clin Invest Med; 1987 May; 10(3):108-16. PubMed ID: 3113795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Yokota K; Oguma K
    J Gastroenterol; 2007 Jan; 42 Suppl 17():21-7. PubMed ID: 17238021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for eradication of Helicobacter pylori infection in duodenal ulcer disease.
    Malfertheiner P; Domínguez-Muñoz JE
    Clin Ther; 1993; 15 Suppl B():37-48. PubMed ID: 8205594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of peptic ulcer disease and current trends in therapy.
    Desai JK; Goyal RK; Parmar NS
    Indian J Physiol Pharmacol; 1997 Jan; 41(1):3-15. PubMed ID: 10225026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gastroduodenal ulcer before and after Helicobacter pylori].
    Bommelaer G; Stef A
    Gastroenterol Clin Biol; 2009; 33(8-9):626-34. PubMed ID: 19682812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.